Mixing Retatrutide and Tirzepatide: Should You Combine Them?

Retatrutide's current status: still in trials, not in pharmacies

Retatrutide is a triple-agonist peptide being developed by Eli Lilly, it targets GIP, GLP-1 and glucagon receptors simultaneously. Phase 2 trial data published in 2023 reported substantial average weight reduction over 48 weeks, which is precisely why it has generated so much interest online. That excitement is understandable. But phase 2 data is not the same as a licensed medicine. As of summer 2026 retatrutide is in phase 3 development; no regulatory body, including the MHRA, has approved it for any use in any patient population. You cannot obtain it through a UK pharmacy (licensed or otherwise) and any seller claiming to offer it is operating entirely outside the regulated supply chain. The comparison between retatrutide and Mounjaro is a genuinely interesting scientific question; it is not yet a clinical one a prescriber can act on.

What combining two gut-hormone agonists would actually mean

Tirzepatide already activates both GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity to that same dual action. If you have been reading about combining retatrutide and tirzepatide, it is worth understanding that this would mean overlapping stimulation of at least two shared receptor pathways simultaneously, with no studied pharmacokinetic data on the interaction. The practical consequences are not theoretical: additive nausea, vomiting and diarrhoea are likely; the risk of dehydration and secondary kidney stress would increase; and in people with any glucose-regulation issues, compounded effects on insulin secretion could cause hypoglycaemia. The NHS medicines information for tirzepatide sets out the known side-effect profile for that medicine alone, combining it with a second, unstudied agent removes every safety assumption those data provide. There is no dose, no titration schedule, no monitoring protocol, and no clinical guideline that covers this scenario. Our clinical team reviews every consultation individually, and this is precisely the kind of question a prescriber is the right person to field.

The real decision: what is your goal and which licensed path serves it

If the research that brought you here was driven by a feeling that standard treatment isn't moving fast enough, or curiosity about whether something newer and stronger is available, that is a completely fair position to be in. Tirzepatide at its highest licensed dose of 15mg produced average weight loss of around 20–21% over 72 weeks in the SURMOUNT-1 trial, as published in the New England Journal of Medicine. That is meaningful evidence. Retatrutide may one day offer a further option, but it cannot be prescribed today. The page on moving from tirzepatide to retatrutide covers what that transition might look like once approval comes, for now it remains a forward-looking question. On the cost side, our guide to Mounjaro pricing in the UK sets out what private treatment actually involves, which matters if you're weighing options. The licensed choice available right now is tirzepatide, prescribed through a regulated pathway, with a clinical review at every step.

Red flags: sellers offering unlicensed combinations

If you have encountered any source (a website, a social media seller, a compounding service) offering retatrutide for purchase now, or offering a combined product, our page on whether you can mix tirzepatide and retatrutide explains clearly why no legitimate service would offer this, and why you should treat any seller who does as a serious warning sign. The MHRA has warned consistently about counterfeit and unlicensed weight-loss injectables circulating online; around 20 million doses of illegally traded weight-loss medicines worth approximately £45m were seized in 2025 alone. Unlicensed products carry no quality assurance, no verified contents and no accountability if something goes wrong. Reporting suspect sellers is straightforward via the MHRA's Yellow Card scheme. Any legitimate route to weight management treatment in the UK starts with a prescription from a clinician who has assessed you, not a checkout button on an unverified site. If you want to talk through where tirzepatide fits for you specifically, our prescribers are available seven days a week.